Financial Performance - Royal Bank of Canada (RBC) reported record results, driven by a 29% year-over-year increase in reported net income available to common shareholders[8, 16] - Adjusted net income increased by 25% year-over-year[8, 16] - Pre-Provision, Pre-Tax Earnings (PPPT) grew by 29% year-over-year[8, 16] - Revenue increased by 14% year-over-year to $17209 million[16] - All-bank operating leverage was 103%[8] - The all-bank efficiency ratio was 545%[8] Segment Performance - Personal Banking net income increased by 20% year-over-year[8, 16] - Commercial Banking net income increased by 5% year-over-year[8, 16] - Wealth Management net income increased by 33% year-over-year[8, 16] - Capital Markets net income increased by 45% year-over-year[8, 16] Capital and Dividends - The CET1 ratio was 135%, up 30 bps quarter-over-quarter[8, 20] - RBC repurchased 48 million shares for $987 million[8, 21] - The dividend increased by $010 or 6% quarter-over-quarter[8]

LOTIS-7 Clinical Trial Results and Strategy - The LOTIS-7 trial (ZYNLONTA + glofitamab) showed an overall response rate (ORR) of 89.8% (44/49 patients) in 2L+ LBCL patients[37] - The complete response (CR) rate in the LOTIS-7 trial was 77.6% (38/49 patients)[41] - In the LOTIS-7 trial, 6 out of 8 patients previously treated with CAR-T achieved a CR[41] - Grade 3 or higher treatment emergent adverse events (TEAEs) occurred in >5% of patients, including neutropenia (32.7%), GGT increased (16.3%), and anemia (10.2%)[40] - Grade 5 AEs occurred in 4.1% (2/49) of patients in the LOTIS-7 trial[40] - Cytokine release syndrome (CRS) of any grade was observed in 36.7% (18/49) of patients in the LOTIS-7 trial[47] Market Opportunity and Revenue Potential - ZYNLONTA has a U S peak revenue potential of $600 million to $1 billion in DLBCL and indolent lymphomas[56] - The company believes LOTIS-7 has the potential to be the leading bispecific combination regimen for patients with access to complex therapies[17] - The company believes LOTIS-5 has the potential to be the leading regimen for patients who will not receive complex therapies[17] Upcoming Milestones - The company expects full enrollment of 100 patients at selected dose for LOTIS-7 in 1H2026[59] - The company expects to share topline results for LOTIS-5[59]

Glencore's Strategic Priorities - Glencore aims to be among the world's largest copper producers, with approximately 1.4Mt of incremental long-life annual copper production progressing through planning and approval phases[20, 291] - The company focuses on long-term value creation for shareholders, with $25.3 billion in announced shareholder returns since 2021[23, 294] - Glencore is optimizing its operating structures to promote accountability and delivery[21, 292] Copper Production and Growth - Glencore targets approximately 1.6Mt of copper production by 2035[51] - The company's base copper portfolio aims to return to 1Mt by 2028[47] - The copper project pipeline includes projects with a total indicative capex of approximately $23.4 billion and an average LOM CuEq production of 1410ktpa[52] Financial Performance and Returns - Glencore has announced $25.3 billion in shareholder returns from 2021 to 2025, including base cash distributions, special cash distributions, and buybacks[241] - Approximately 1.6 billion shares have been repurchased, representing approximately 14% of current shares eligible for distributions[41, 243] - The company's copper business can self-fund its full indicative growth pipeline[234] Operational Efficiency and Portfolio Optimization - Glencore has sold or shut down approximately 35 assets since 2021[39] - The company has identified approximately $1 billion of recurring cost-saving opportunities across more than 300 initiatives, expected to be fully delivered by the end of 2026, with over 50% already locked in for 2025[41] - Glencore has streamlined its industrial operating structure, eliminating approximately 1000 roles[67]

Financial Performance Highlights - Macy's Inc's comparable owned-plus-licensed-plus-marketplace (O+L+M) sales increased by 3.2% compared to 3Q24[8, 44] - Adjusted diluted earnings per share (EPS) was $0.09[9, 10] - Net sales were $4.7 billion, a decrease of 0.6% compared to 3Q24, but increased by 2.9% excluding the impact of store closures[40] - Comparable owned sales increased by 2.5% compared to 3Q24[42] - Go-Forward business comparable O+L+M sales increased by 3.4% compared to 3Q24[46] Brand Performance - Macy's nameplate comparable O+L+M sales increased by 2.0% compared to 3Q24[14, 49] - Macy's Go-Forward business comparable O+L+M sales increased by 2.3% compared to 3Q24[14, 49] - Bloomingdale's comparable O+L+M sales increased by 9.0% compared to 3Q24[17, 49] - Bluemercury comparable owned sales increased by 1.1% compared to 3Q24[24, 49] Operational Improvements - Inventory increased by 0.7% compared to 3Q24[29, 50] - Order-to-ship days improved by 11.3%[29, 30] Guidance - The company expects FY25 comparable O+L+M sales to be approximately flat to +0.5% vs FY24 and adjusted diluted EPS to be $2.00 to $2.20[62]

RAPIDe-3 Study Design and Demographics - The RAPIDe-3 study was a double-blind crossover trial evaluating deucrictibant IR 20 mg versus placebo for HAE attacks[17] - The efficacy analyses were based on 88 paired attacks[19] - The study enrolled 134 participants, including 10 adolescents (7.5%) and 124 adults (92.5%)[20] - The median age of participants was 38 years, and 56.7% were female[23] Efficacy Endpoints - Deucrictibant significantly reduced the time to onset of symptom relief to 1.28 hours compared to placebo (p < 0.0001)[35] - Deucrictibant significantly reduced the time to End of Progression (EoP) to 17.47 minutes compared to placebo (p < 0.0001)[38] - Deucrictibant significantly reduced the time to substantial symptom relief by PGI-C to 2.85 hours compared to placebo (p < 0.0001)[42] - Deucrictibant significantly reduced the time to substantial symptom relief by PGI-S to 2.41 hours compared to placebo (p < 0.0001)[47] - Deucrictibant significantly reduced the time to complete symptom resolution to 11.95 hours compared to placebo (p < 0.0001)[51] Treatment and Safety - 83% of attacks were treated with a single capsule of deucrictibant[54] - 93.2% of attacks were treated without rescue medication with deucrictibant versus 63.6% with placebo[54]

Financial Performance - Diluted EPS from continuing operations was $1.20, and adjusted diluted EPS from continuing operations was $1.21[8] - Dollar Tree segment gross margin expanded by 40 bps to 35.8%[9] - Adjusted operating margin contracted 30 bps to 7.3%[9] Sales and Comparable Store Sales - Dollar Tree's comparable store sales increased by 4.2%, driven by a 4.5% increase in average ticket and a 0.3% decrease in traffic[9] - Consumables comparable sales grew by 3.5%, while discretionary comparable sales grew by 4.8%[9] - Discretionary mix increased by 40 bps to 50.5%[9] Real Estate and Store Conversions - The company opened 106 new Dollar Tree stores, ending the quarter with 9,269 open stores[9] - 1,744 multi-price 3.0 format store conversions were completed year-to-date, remaining on track to reach the full-year target of 2,000[9] - 55 Family Dollar combo store conversions to full Dollar Tree stores were completed[9] Balance Sheet and Cash Flow - Inventory decreased by 5% year-over-year, a reduction of $143 million, while sales increased by 9.4%[9] - Year-to-date free cash flow from continuing operations was $88 million, and cash and cash equivalents at quarter-end totaled $595 million[9] - The company repurchased 4.1 million shares in Q3 for $399 million including excise tax, and an additional 1.7 million shares were purchased subsequent to quarter-end for $176 million[9] - Year-to-date, 16.7 million shares were repurchased for $1.5 billion at an average price of $90 per share, representing 8% of shares outstanding at the beginning of the year[9] Updated Outlook for Fiscal Year 2025 - Dollar Tree sales are projected to be between $19.35 billion and $19.45 billion[33] - Comparable sales for Dollar Tree are expected to increase by 5.0% to 5.5%[33] - Adjusted diluted earnings per share are projected to be between $5.60 and $5.80[33]

HOPE-3 Trial Overview - The HOPE-3 Phase 3 trial met both the primary endpoint (PUL v20) and the key secondary cardiac endpoint (LVEF), achieving statistical significance with p=003 and p=004 respectively[27] - Statistical significance was achieved in all type 1 error controlled secondary endpoints[27] - The trial involved 106 patients randomized 1:1 to Deramiocel or placebo[13, 14] - The study population consisted of late-ambulatory patients with DMD and 10MWR > 10 seconds[15] Safety Profile - In the Placebo group, 827% (43/52) experienced any Treatment Emergent Adverse Events (TEAEs), while in the Deramiocel group, 943% (50/53) experienced any TEAEs[18] - TEAEs related to the Investigational Product (IP) or administration procedure were reported in 365% (19/52) of the placebo group and 830% (44/53) of the Deramiocel group[18] - Serious TEAEs occurred in 96% (5/52) of the placebo group and 19% (1/53) of the Deramiocel group[18] Deramiocel Potential - Deramiocel is a potential first-in-class therapy designed to treat DMD skeletal and cardiomyopathy[27] - The company plans to submit a response to the Complete Response Letter incorporating HOPE-3 data, following prior alignment with the FDA[27]

Financial Performance & Growth - Clover Health achieved Adjusted EBITDA profitability in 2025 and anticipates GAAP Net income in FY26[9, 25] - The company experienced a +33% year-over-year increase in Medicare Advantage (MA) membership[9] - Clover Health's Insurance revenue grew by +39% year-over-year in 3Q YTD[26] - Adjusted SG&A as a percentage of total revenues improved by 370 bps year-over-year in 3Q YTD[23] Clover Assistant & Clinical Outcomes - Clover Assistant is correlated with ~36 months earlier diagnosis & treatment for diabetes on average[18] - Clover Assistant is correlated with ~18 months earlier diagnosis of Chronic Kidney Disease (CKD) stage 3 & higher on average[18] - Clover Assistant is correlated with 18% lower all-cause hospitalizations & 25% lower 30-day readmissions for Congestive Heart Failure (CHF)[18] Market Positioning & Strategy - Clover Health is targeting a ~$500 billion market with >35 million seniors in Medicare Advantage (MA)[9] - The company's PPO-first approach covers 97% of its membership[9] - Clover Health's Medicare Advantage PPO plans received a score of 472 out of 5 Stars on HEDIS Measures for Star Rating Year 2026[51]

L'Oréal USA Overview - L'Oréal USA is the 1 beauty manufacturer in the U S [8, 23] - L'Oréal USA represents 27% of subsidiary sales in the North America zone [9] - Over 75% of L'Oréal USA's units are produced in North America [10] - L'Oréal USA has experienced 7X growth since 1995 [15] Market Position and Growth - L'Oréal has a 16% share of market (SOM) in the total beauty market, which is more than 2X larger than the 2 competitor [24] - The U S is the 1 beauty market in size and growth worldwide, accounting for 27% of the global market with a +5% change [38, 39] - L'Oréal is accelerating faster than the market, gaining major momentum with a +5% increase in Q3 [50, 52] Category Performance - L'Oréal's haircare is growing 3X the market rate [56] - In makeup, all of L'Oréal's CPD brands are outperforming the market year-to-date [64] - L'Oréal has a 34% share of market in mass makeup [73] Channel Strategy - E-commerce accounts for 26% of L'Oréal's business and is accelerating at +2X the market rate year-to-date [92] - B&M (Brick and Mortar) remains a priority, representing 65% of the total market [98]

Claim 5 Achievements (2020-2024) - Hugo Boss surpassed its original €4 billion sales target in 2023, two years ahead of plan[16] - Sales CAGR from 2020 to 2024 was +22%[17] - The company almost doubled sales with licenses, from approximately €60 million in 2020 to approximately €110 million in 2024, representing a +14% CAGR[53] - Online sales more than doubled, growing from approximately €04 billion in 2020 to approximately €08 billion in 2024, with a CAGR of approximately 25%[70] - US sales almost tripled since 2020, increasing from approximately €02 billion to approximately €07 billion[74] Focus on Excellence (Claim 5 Touchdown) - The company is prioritizing excellence with efficiency within Claim 5 Touchdown[103] - Marketing investments will be maintained at approximately 7% of sales[119, 360] - The company aims to reduce style complexity in BOSS Menswear by -20% by 2028 compared to 2024, and by -25% compared to 2020[216] - The company is targeting inventory reduction toward 20% of sales[217, 304, 385] Financial Ambition - The company is targeting normalized capital expenditure at a level of 3% – 4% of sales[304, 383] - The company is aiming for annual Free Cash Flow (FCF) of approximately €300 million, excluding IFRS 16, and approximately €500 million including IFRS 16[322, 387]